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Oxidativní stres je jedním z významných faktorů, které vedou k poškození a smrti 
neuronálních buněk. Děje se tak v důsledku vzniku reaktivních kyslíkatých radikálů, 
které se podílejí na patogenezi neurodegenerativních onemocnění, např. Alzheimerovy 
choroby (AD). 
Vědecké studie dokazují, že přírodní kumariny vykazují antioxidační vlastnosti, a 
mohly by tudíž představovat nové možnosti léčby neurodegenerativních chorob. 
Esculetin (ESC), scopoletin (SCOP), fraxetin (FRAX) a daphnetin (DAPH) patří do 
skupiny fenolických kumarinů a vzhledem ke katecholové skupině a α-pyronovém 
kruhu vykazují značné antioxidační vlastnosti. 
V této práci jsme se zabývali antioxidačními a neuroprotektivními vlastnostmi ESC, 
SCOP, FRAX a DAPH na lidských neuronálních buňkách (SH-SY5Y). Zkoumali jsme 
aktivitu proti 2,2-difenyl-1-pikrylhydrazylu (DPPH), vzniku reaktivních kyslíkatých 
radikálů a cytotoxicitě způsobené terc-butyl hydroperoxidem (t-BuOOH). Dále byla 
testována schopnost ESC zvýšit hladiny cytosolového glutationu (GSH) a inhibovat 
cytotoxicitu způsobenou oligomery Aβ₁₋₄₂ (OAβ1-42). 
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Oxidative stress represents one of the crucial factors leading to the neural cell damage 
and death. This process occurs due to generation of reactive oxygen radicals that 
contribute to the pathogenesis of neurodegenerative disorders such as Alzheimer's 
disease (AD). Recent scientific studies have reported that natural coumarins possess 
antioxidant properties and might therefore represent new treatment option in the 
therapy of neurodegenerative diseases including AD. In particular, phenolic coumarins 
comprising esculetin (ESC), scopoletin (SCOP), fraxetin (FRAX) and daphnetin 
(DAPH), possess considerable antioxidant activities due to the catechol group and the 
α-pyrone ring. 
In this study, we investigated the antioxidant and neuroprotective effects of ESC, 
SCOP, FRAX and DAPH using human neuronal (SH-SY5Y) cells and evaluated 
activity of these compounds against DPPH and ROS formation and cytotoxicity 
induced by tert-butyl hydroperoxide (t-BuOOH). In addition, we tested the ability of 
ESC to increase cytosolic glutathione (GSH) levels and inhibit the cytotoxicity 
induced by Aβ₁₋₄₂ oligomers (OAβ1-42). 
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GMCSF Granulocyte macrophage colony-stimulating factor 
GSH Glutathione 
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IDE Insulin-degrading enzyme 
IL-1α Interleukin 1α 
IL-6 Interleukin 6 
Keap1 Kelch-like ECH-associated protein 1 
MAO Monoamine oxidase 
MTT Salts of tetrazole 
Nrf2 NF-E2 related factor 2 
OAβ1-42 Oligomers of OAβ1-42 
ROS Reactive oxygen species 
SCOP Scopoletin 
SH-SY5Y Cells of neuroblastoma 
t-BuOOH Tert-butylhydroperoxide 
TNFR1 TNF Receptor 1 
TNFR2 TNF Receptor 2 




Alzheimer's disease (AD) is one of the most common neurodegenerative illnesses. Its 
incidence increases with age (with the highest frequency around the age of 65). It is 
characterized by a memory loss, poor sleep quality, emotional changes, anxiety, 
depression and cognitive deterioration.1 
AD is a multifactorial disease with several mechanisms including processing of 
amyloid precursor protein (APP) to amyloid β peptide, hyperphosphorylation of tau 
protein, abnormal spiral filaments in neurons and increased oxidative stress. 
Neurotransmitters such as glutamate and serotonin are also affected during AD.1,2 
There is also an interest in mechanisms propagated by obesity, type-2 diabetes 
mellitus, metabolic syndrome, stress, sedentariness and dietary overconsumption of 
saturated fat and refined sugars.1 
AD correlates with the disproportional loss of synapses between neurons, while 
neurofibrillary tangles of hyperphosphorylated protein tau are directly related to the 
severity of AD and they can serve as a pathological marker.1 
The deficiency in the neurotransmitter acetylcholine (ACh) and cholinergic 
neurotransmission dysfunction in brain of AD patients seems to play a fundamental 
role in a memory deterioration. Acetylcholinesterase is the enzyme that degrades ACh, 
and accelerates amyloid-β peptide formation, which is one of the pathological sign of 
the disease.3 
Unfortunately, there is no effective cure for AD available so far and current treatment 
strategies resolve primarily symptomatic problems associated with AD. Efforts to 
develop new therapeutic approaches are focused on inhibition of acetylcholinesterase 
(AChE) to improve cholinergic neurotransmission between neurons.2 
Several of the cholinesterase inhibitors, that are currently in use, like donepezil, 
rivastigmine, galantamine and tacrine, have some adverse side-effects; e.g. 
gastrointestinal disorders, nausea and vomiting, therefore there has been a scientific 
effort in researching natural inhibitors of AChE, butyrylcholinesterase (BChE) and 
beta-site APP cleaving enzyme 1 (BACE1) with safer profiles.2,4 
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Natural compounds with ''multi target'' mechanisms could be important in the 
development of new compounds with neuroprotective features. 
Recent studies demonstrated that exactly coumarins possess this neuroprotective 
ability. Coumarins are also able to inhibit enzymes such as MAO, AChE and γ-
secretase. They also show the effect against excitotoxicity mediated by glutamate. 
Recently they showed also their capacity to promote the release of neuroprotective 
factors like brain-derived neutrophic factor (BDNF) in the cerebral cortex and to 
oppose neuroinflammatory processes by reducing the release of pro-inflammatory 
cytokines and neurotoxic factors that are induced by Aβ protein. 
  
 10 
5 Theoretical part 
5.1 Mechanisms involved in Alzheimer's disease 
5.1.1 β-amyloid protein 
β-amyloid protein (Aβ) is derived from a transmembrane amyloid precursor protein 
(APP). APP is metabolized by enzymatic actions of BACE-1, α-secretase and γ-
secretase. Aβ peptides are formed as a result of these enzymatic reactions and they are 
constituted from 36 to 43 amino acids. Specific peptides are formed due to the action 
of γ-secretase. Aβ40 is the most common form of this peptide. On the other hand, Aβ42  
is more prone to aggregation and consequent extracellular formation of multimers or 
fibrils.5 These amyloid deposits are surrounded and attacked by reactive astrocytes and 
microglia. This process can induce irreversible neuronal cell death and cognitive 
impairment, loss of memory and physical deterioration. These senile plaques are 
formed principally in hippocampus, amygdala and cortex.1 
 
Fig. 1: Cleavage of APP into β-Amyloid by BACE-1, α-secretase and γ-secretase.6 
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A possible approach to reduce β-amyloid formation is to inhibit β-secretase (BACE1) 
which is a transmembrane enzyme responsible for the production of β-amyloid 
peptide. Inhibition of AChE and BChE (the enzyme similar to AchE, which also plays 
an important role in the pathogenesis of AD) is also an effective drug strategy to treat 
AD.3 
Aβ is degraded by the insulin-degrading enzyme (IDE), the same one that decomposes 
insulin. High levels of insulin then influence Aβ clearance.1 
In addition, growth hormone (GH) released from the anterior pituitary can influence 
repairing processes and growing in CNS. The activity of this hormone declines with 
age. A lower amount of GH correlates also with an increase of total body and visceral 
fat and decreased physical activity. There is also evidence that GH influences the CNS 
cognitive processes.1 
 
5.1.2 Neurofibrillary Tangles 
Formation of intracellular neurofibrillary tangles is another process that influences 
negatively the pathology of AD.5 
The tangles are the result of an incorrect configuration of microtubules that stabilize 
protein tau. Neurofibrillary tangles are formed by paired helical filaments. They can 
accumulate within neuronal cells leading to a destabilization and dissociation of 









Senile plaques are the source of infection and inflammatory response, which is 
promoted by fibrillation of Aβ.1 Consequently immune cells like microglia, astroglia, 
pro-inflammatory cytokines (TNFα, IL-6, IL-1α, GMCSF), chemokines, caspases, 
complement system, nitric oxide and reactive oxygen species are activated.8 
TNFα binds and transduces the signal by two TNF receptors: TNF Receptor 1 
(TNFR1) and TNF Receptor 2 (TNFR2). TNFR1 causes damages through its pro- 
inflammatory effects. On the other hand, TNFR2 has neuroprotective properties. It is 
considered an activator of the NF-κB pathway, which leads to an anti-apoptic 
processes and thus it contributes to cell survival and neuronal protection.1 
Selective inhibition of TNFR1 and/or activation of TNRF2 can possibly inhibit the 
neuroinflammatory pathway involved in neurodegenerative processes and utilize the 




Fig. 3: Neuroinflammation and pro-inflammatory substances involved in the pathology of 
AD.9 
5.1.4 Oxidative stress 
Oxidative stress is an imbalance between production of reactive oxygen species (ROS) 
and antioxidant defence mechanisms that lead to accumulation of ROS.10 
ROS are a group of reactive molecules that are derived from oxygen. ROS are usually 
short-lived and highly reactive because they contain an unpaired valence electron. 
Thanks to the electron they can react quickly with another radical or another 
molecule.11,12 ROS are generated by exogenous and endogenous stimuli. Ultra violet 
light (UV) and ionizing radiation represent the exogenous source of ROS formation. 
Endogenous generation of ROS is mediated by mitochondrial and non-mitochondrial 
ROS-generating enzymes, e.g. nicotinamide adenine dinucleotide phosphate oxidase 
(NADPH), the major sources of ROS production, and further xanthine oxidase (XO), 





Fig. 4: Common reactive oxygen species.12 
 
Although ROS are considered the molecules that affect organism negatively, they can 
promote physiological functions in cellular signalling related to the cardiovascular 
system, defence mechanisms of the immune system, regulation of mitosis, 
proliferation, migration, cell survival and apoptosis.11,14,15 ROS can also affect the 
transcription factors, which regulate cellular response to ROS. Increased ROS 
concentration may cause activation of the antioxidant defence mechanisms. NF-E2 
related factor 2 (Nrf2) is one of the redox-sensitive transcription factors. It is activated 
by ROS and it leads to an expression of antioxidant enzymes like superoxide 
dismutases, peroxiredoxins and glutathione peroxidases.16 Nrf2 is normally present in 
cytoplasm thanks to a suppressor protein Kelch- like ECH- associated protein 1 
(Keap1). This complex impedes the translocation of Nrf2 to the nucleus and maintains 
Nrf2 inactive under normal conditions. Higher ROS levels cleave the bond in this 
complex and Nrf2 activates gene transcription.17 
Primarily, the formation of ROS is neutralized by several antioxidant systems 
mentioned before. 
Due to the fact that the brain is one of the most metabolically active organs, it is very 
prone to oxidative stress, because of a high oxygen demand. The redox-active metals 
like iron or copper are involved in catalization and thus formation of ROS Another 
oxidative stress leading causes include high levels of polyunsaturated fatty acids that 
serve as substrates for lipid peroxidation, and low levels of glutathione (GSH), which 
is an endogenous antioxidant.18,19 
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This oxidative imbalance can lead to neuronal damage and can be crucial at the 
begging and progression of AD. The accumulation of Aβ probably induces oxidative 
stress and causes mitochondrial dysfunction and energy defeats. Oxidative stress can 








Coumarins (2H-1-benzopyran-2-one) are heterocyclic compounds constituted of a 
benzene ring attached to an α-pyrone ring. More than 1300 coumarins have been 
identified as secondary metabolites of plants, bacteria and fungi. They can be isolated 
from the tonka bean (Dipteryx odorata Wild), and they are also present in several plant 
families like Rutaceae, Caprifoliaceae, Oleaceae and Apiaceae. Coumarins can be 
found in vegetables, fruits, seeds, nuts, coffee, tea and wine, but they can be prepared 
also synthetically. Coumarins are non-polar compounds with a short half-life, which 
leads to their low bioavailability. They are metabolized by cytochrome P-450-linked 
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mono-oxygenase (CYP 2A6) in liver, forming their primary metabolite 7-
hydroxycoumarin- the active form of coumarins.21 
The physicochemical properties and therapeutic applications of natural coumarins 
depend on the substitution of coumarin's structure.22 
Coumarins have a wild range of biological effects including anti-inflammatory, 
antioxidant, neuroprotective, antibacterial, antifungal, antihypertensive, 
antitubercular, anticonvulsant, antiadipogenic, anticancer, antiviral and anticoagulant 
properties.22 
The strong action of coumarins on the central nervous system seems to be a very 
important biological property, and, thus, they are a potential resource for the 
prevention and therapy of CNS diseases.3 
Some studies showed that substitution at C7 of the coumarin nucleus with a small 
functional groups (e.g. hydroxyl, methoxy) had a lower inhibitory effect on AChE, 
while attaching bigger substituent increased the inhibitory activity of coumarins. 
Substitution at C3 modulated the AChE activity, as well as the activity of MAO-B. 
Positioning of methyl groups at C3 and C4 leads to formation of more active 
compounds towards both enzymes, while monosubstitution at position C4 with phenyl, 









Fig. 7: Chemical structures of tested series of coumarins. 
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Esculetin is a coumarin isolated from Cichorium intybus and Bougainvilea spectabilis 
Wild (Nyctaginaceae). Esculetin inhibits the cyclooxygenase and lipoxygenase 
enzymes, which explains its anti-inflammatory activity. It shows also anticancer, 
antioxidant and antiadipogenic properties and neuroprotective activity.22 
It exhibits also an apoptotic action by decreasing the cleaved caspase-3 level, the up-
regulation of the expression of Bcl-2, and the down-regulation of Bax expression that 
are two proteins related to apoptosis.3 
 
Scopoletin was isolated from Fraxinus rhynchophylla (Oleaceae) and it shows 
antihypertensive and antiadipogenic features.22 
Scopoletin and its glycoside scopolin were proved as potential AChE inhibitors. In 
vitro activity and in vivo experiments showed that both of these compounds increased 
the extracellular ACh concentration in the rat brain.24  
 
Fraxetin is an ortho-dihydroxylated coumarin isolated from Fraxinus rhynchophylla 
(Oleaceae), which showed antiadipogenic properties.22 
 
Daphnetin is a coumarin isolated from Daphne papyracea (Thymelaeaceae), which 
also determined antiadipogenic features.22 
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6 Aim of the thesis 
The aim of this thesis was to evaluate neuroprotective effects of natural coumarins 
such as esculetin (ESC), daphnetin (DAPH), fraxetin (FRAX) and scopoletin (SCOP) 
using in vitro models.  




7 Experimental part 
Cell culture 
Human neuronal–like SH–SY5Y cells of neuroblastoma were purchased from 
Lombardy and Emilia Romagna Experimental Zootechnic InstituteItaly. 
 
Components of the culture medium 
 Dulbecco's modified Eagle's medium (DMEM) - Lonza Group Ltd- 
Switzerland 
 Stock solution of L - glutamine 200 mM - Sigma Aldrich Chemical St. Louis, 
MO, USA 
Prepared previously by dissolving 0,146 g of glutamine in 5 mL of distilled 
H2O and filtering with 0.22 μm filter of acetate cellulose. 
 Stock solution of penicillin 5000 UI and 5 μg/mL streptomycin - Sigma Aldrich 
Chemical St. Louis, MO, USA 
 Fetal bovine serum (FBS) - Lonza Group Ltd- Switzerland  
Previously deactivated at 57°C for 30 minutes. 
 
Preparation of 10 % FBS medium 
The medium was prepared into sterile containers under sterile conditions. Components 
were mixed in following order: 
 DMEM 88% 
 Penicillin-Streptomycin 1% 
 L-glutamine 1% 
 FBS 10%  
 
 
Preparation of cell cultures  
The cell culture was routinely grown in DMEM supplemented with 10 % FBS, 2 mM 
glutamine, stock solution of penicillin 5000 IU and 5 μg/mL streptomycin using 75 
cm2 cell tissue culture flasks and 37 °C humified incubator with 5 % CO2,. When the 
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cell population reached confluence, EDTA-Trypsin (0.02-0.05%) solution was used 
for cell splitting (1:3 or 1:5 into new flasks every two weeks). 
 
 
Fig. 8: SH-SY5Y cells (optical microscope, magnification 100x) 
 
 
7.1 Materials and methods 
Chemical compounds 
 Esculetin, daphnetin, scopoletin and fraxetin were purchased from Sigma-
Aldrich Chemical (St.Louis, Missouri, U.S.A.). 
 Stock solution of esculetin 20 mM 
Prepared from 1 mL of sterile dimethyl sulfoxide (DMSO) and 3.562 mg of 
ESC  
 Stock solution of daphnetin 40 mM 
Prepared from 1 mL of sterile DMSO and 7.1256 mg of DAPH 
 Stock solution of scopoletin 40 mM 
Prepared from 1 mL of sterile DMSO and 7.6868 mg of SCOP 
 Stock solution of fraxetin 40 mM 
Prepared from 1 mL of sterile DMSO and 8.3268 mg of FRAX 
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Solutions of these coumarins were aliquoted into an eppendorf of 1.5 mL and 
stored at -20 °C. Working solutions were prepared by diluting the stock 
solution in a culture medium or in Hank's balanced salt solution (HBSS). 
 
 β-amyloid peptide 1-42 (Aβ1-42) was purchased from AnaSpec (Freemont, CA, 
USA). 
 
Preparation of peptide 
Peptides were subjected to the denaturation: 1 mg of Aβ1–42 was dissolved in 500 μL 
of 1,1,1,3,3,3-hexafluoro-2-propanol and sonicated for 1 minute at average intensity. 
Prepared solution was consequently sealed with parafilm and left to dissolve for 24 
hours. Subsequently, the solvent was allowed to completely evaporate by leaving the 
peptide solution in a laminar flow for 24 hours. The obtained peptide was utilized for 
preparation of stock solutions of 1 mM Aβ1-42 in sterile DMSO. Stock solutions were 
poured into vials (0.5 mL aliquots) and stored at -20 °C. 
 
Preparation of oligomers 
240 μL of DMEM were added to 10 μL of Aβ1-42 and this mixture was stored at 4 °C 
for 24 hours to allow formation of oligomers (OAβ1-42).  
 
3.4.2 Solutions 
Hank's balanced salt solution (HBSS) without phenol red (Lonza). 
 
Dulbecco's phosphate buffered saline without Ca2+ and Mg2+ 10x (D'PBS) 
(Lonza). 
 
Dulbecco's phosphate buffered saline with Ca2+ and Mg2+ 10x (D'PBS) 
(Lonza). 
 
0.02 – 0.05 % EDTA-trypsin solution (Lonza) diluted by sterile D'PBS 1:10 
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0.25 % eosin solution, prepared from appropriate amount of Eosin B (Sigma Aldrich) 
and D'PBS. 
 
Stock solution of salts of tetrazolium: 30 mg of salts of tetrazolium (MTT) (Sigma 
Aldrich) were dissolved in 6 ml of HBSS and the solution was stored at -20°C 
protected from light. 
 
Experimental solution of MTT was prepared from 1.2 mL of stock solution of MTT, 
which was added into 10.8 mL of HBSS. For the preparation, 0.45 μm filters were 
used and the solutions were prepared in the time of need and protected from light. 
 
Stock solution of 2,2-diphenyl-1-picrylhydrazyl (DPPH) was prepared from 3,94 mg 
of DPPH (Sigma Aldrich) dissolved in 1 mL of ethanol (EtOH). The solution was 
stored at -20°C and protected from light. 
 
Experimental solution of 100μM DPPH was prepared from 180 μL of DPPH, which 
was added into 17.820 μL of EtOH.  
 
Experimental solution of t-BuOOH (400 μM) was prepared from an original 
solution of t-BuOOH (Sigma Aldrich Chemical St. Louis, MO, USA). 50 μL of 
original solution were added to 420 μL of HBSS to prepare a stock solution. 
Consequently, 10 μL of stock solution and 990 μL of HBSS were mixed to prepare 
an intermediate solution with the concentration of 10 mM. According to a 
calculation and consideration of 12 mL of working solution for 96 well plate, 480 
μL of intermediate solution and 11.52 mL of HBSS were mixed 
 
Stock solution of 2',7'-dichlorohydrofluorescein diacetate (H2DCF-DA) was prepared 
from 2.5 mg of H2DCF-DA (Sigma Aldrich) dissolved in 1 mL of dimethyl sulfoxide 
(DMSO). The solution was stored at -20°C protected from light. 
 
 24 
10 μg/mL experimental solution of H2DCF-DA was prepared from 50 μL of H2DCF-
DA stock solution, which was added into 12.450 μL of HBSS. 
 
Stock solution of monochlorobimane (MCB) (Sigma Aldrich) was prepared from 25 
mg of MCB dissolved in 2 ml of 95% EtOH. The solution was stored -20°C protected 
from light. 
 
50 µM experimental solution of MCB was prepared from 22 µl of MCB stock solution, 
which was added into 24.178 µl of D'PBS. The solution was prepared at the time of 




7.2.1 Evaluation of intrinsic antioxidant activity  
Principle of the assay 
DPPH is an organic chemical compound, 2,2-diphenyl-1-picrylhydrazyl. It is a blue-
dark-colored crystalline molecule with an unpaired electron. DPPH is a well-known 
radical and a trap ("scavenger") for other radicals. Therefore, a level of DPPH 
reduction is utilized as an indicator of the radical nature of tested molecules. By 
reacting the DPPH with an antioxidant compound capable of reducing the radical 
compound, a dark blue discoloration of the solution occurs due to the disappearance 
of the radical and a solution becomes yellow. This colour changes allow visual 
monitoring of this neutralization reaction, and the amount of trapped radicals can be 
expressed due to the change in optical absorption.25,26 
 
 
Fig. 9: The scheme of DPPH neutralization. 
 
Measurement 
The suspension of SH-SY5Y cells at density of 2.105 cells/mL in 10 % FBS medium 
was prepared. Consequently, 100 μL of suspension were added into black wells of the 
96-well plate, while no cells were added into white wells. The well plate was incubated 
for 24 hours at 37 °C and 5% of CO2 to allow a formation of monolayer. 
To evaluate the intrinsic antioxidant activity of the compounds, the standard of 100 
μM DPPH was used.  
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The amount of 50 μL of ESC, SCOP, FRAX and DAPH solutions of certain 
concentrations (2.5, 5, 10, 20, 40 μM), dissolved in EtOH, were dispensed in a 96-well 
plate. At least three repetitions of the experiment were made for higher accuracy.  
Further, 150 μL of 100 μM experimental solution of DPPH were added into each well 
and 200 μL in wells of negative control. The 96-well plate was further incubated for 
30 minutes at room temperature protected from light. After incubation, the 
discoloration was quantified through the measurement of absorbance at λ = 492 nm by 
a multilabel plate reader (VICTORTM X3, PerkinElmer, Massachusetts, USA). 
 
Expression of results 
The results were expressed as a percentual inhibition of DPPH radical with coumarin 
compounds in comparison to a control sample. The percentage was calculated using 
the following formula:  
 





ODdpph – ODcoumarins = Optical density of the solutions formed by DPPH and 
coumarins 
ODdpph = Optical density of the DPPH solution  
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7.2.2 Determination of ROS intracellular formation 
Principle of the assay 
For this experiment, t-BuOOH was utilized as an exogenous inductor of oxidative 
stress. This organic peroxide is usually used as a model substance for evaluation of 
mechanisms of cellular alterations resulting from oxidative stress in cells. 
The intracellular ROS formation was evaluated thanks to 2',7'-
dichlorodihydrofluorescein diacetate (H2DCF-DA), a non-polar and non-fluorescent 
molecule, which is able to diffuse rapidly into the living cells. Consequently, the 
H2DCF-DA is hydrolysed by intracellular esterase to 2',7'-dichlorodihydrifluorescein 
(H2DCF). The H2DCF is a polar molecule, which remains trapped in the cytoplasm, 
where it becomes oxidized because of a presence of ROS. As a result a fluorescent 
molecule, 2',7'-dichlorofluorescein (DCF), is formed. The fluorescence intensity is 
directly proportional to the level of DCF created in cells, und thereby indirectly also 




Fig. 10: The scheme of intracellular ROS concentration evaluation. 
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Measurement 
A cellular suspension of SH-SY5Y with a density of 3x105 cell/mL was prepared in 
10% FBS medium. Consequently, 100 μL of suspension were spread into a 96-well 
plate and it was inserted into an incubator for 24 hours in a condition of 37 °C and 5% 
of CO2 to allow adhering to the surface. 
The cells were treated by adding 100 μL of DMEM with different concentrations of 
ESC, SCOP, FRAX and DAPH; while in the negative controls, it was added 100 μL 
of DMEM. Further, cells were incubated in the same conditions as mentioned before 
for 2 and 24 hours. At least three repetitions of the experiment were made for higher 
accuracy. 
The content of the plate was removed with an inversion of a plate and each well was 
washed with 150 μL of HBSS, then 100 μL of experimental solution of H2DCF-DA 
were added into each well. The well plate was further incubated for 30 minutes at room 
temperature protected from light. After incubation, the solution of H2DCF-DA was 
eliminated by the inversion of a plate and the cells were washed with 150 μL of HBSS. 
200 μL of HBSS with 200 μM t-BOOH were added to each tested plate. 100 μL of 
HBSS with 200 μM t-BOOH and 100 μL of pure HBSS were added into positive 
controls, while 200 μL of HBSS were added into the negative controls. 
After 30 minutes, the fluorescence measurement was performed by flow cytometry 
(VICTORTM, PerkinElmer, Massachusetts, USA) at λexcitation = 485 nm and λemission = 
535 nm.  
 
Expression of results 
The intracellular formation of ROS was expressed as the increase of fluorescence using 
this formula: 





Fc = fluorescence of cells treated with t-BuOOH and with different concentrations of 
coumarins 
Fnc = fluorescence of untreated cells 
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7.2.3 Determination of intracellular glutathione levels 
Principle of the assay 
Glutathione (GSH) is a tripeptide synthesized from glutamate, cysteine and glycine.  
GSH is one of the most important antioxidants, which protects cells against oxidative 
stress. In the brain, the enzyme glutamylcysteine synthetase produces GSH utilizing 
glutamate and cysteine as substrates. This dipeptide is then associated with glycine by 
the catalization of glutathione synthetase to form a complete GSH. Several studies 
have also demonstrated that GSH is involved in inhibiting apoptic cell death and DNA 
damage. Reduced GSH contains a free thiol group and reacts non-enzymatically with 
ROS, which leads to their removal. This reaction promotes a formation of glutathione 
disulfide (GSSG), which is the final product of GPX reactions. Reduced GSH can be 
regenerated from glutathione disulfide by the reaction with glutathione reductase 
within the transfer of electrons from NADPH to glutathione disulfide.28 
When cells are exposed to increased levels of oxidative stress, GSSG accumulates and 
the ratio of GSH to GSSG decreases. Therefore, the determination of the GSH/GSSG 
ratio and the quantification of GSSG are useful indicators of oxidative stress in cells 
and tissues. Higher levels of GSH indicate bigger resistance of SH-SY5Y cells to 
neuronal death, in terms of apoptosis.28 
 
To measure the intracellular glutathione (GSH) formation, monochlorobimane was 
used (MCB, Fluorescent Dyes, Los Angeles, Ca, U.S.A). This MCB probe is specific 




Fig. 11: Formation of fluorescent complex of GSH with MCB. 
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Measurement 
The suspension of SH-SY5Y cells at density of 2 x 105 cells/mL in 10 % FBS medium 
was prepared. Consequently, 100 μL of suspension were added into black wells of the 
96-well plate, while no cells were added into white wells. The well plate was incubated 
for 24 hours at 37 °C and 5% of CO2 to allow a formation of monolayer. 
The content of the plate was eliminated and SH-SY5Y cells were treated with 100 μL 
of DMEM with ESC (10 μM, 20 μM, 40 μM), while in the negative controls, it was 
added 100 μL of DMEM. Further, cells were treated with oligomeric Aβ1–42 (2 μM) 
(pre-treatment). 
For the second experiment, cells were treated with esculetin (10 μM, 20 μM, 40 μM) 
and oligomeric Aβ1–42 (2 μM) (co-treatment) all at once. 
Cells were consequently incubated at the same conditions as before for 24 hours. At 
least three repetitions of the experiment were made for higher accuracy. 
At the end of the treatment, the medium was eliminated from the wells and the cells 
were incubated with 100 μL of MCB (50 μM) for 30 minutes protected from light. The 
GSH levels were measured by a multilabel plate reader (VICTORTM X3) at λexcitation 
= 360 nm and λemission = 465 nm. 
 
Expression of results 
The increase of fluorescence was calculated using the following formula: 
 





Fi = Fluorescence of the cells treated with coumarins, after subtracting the control 
Fni = Fluorescence of the control solution 
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7.2.4 Determination of neuronal viability 
Principle of the assay 
The MTT assay is a colorimetric method for evaluating neuronal viability. 
Oxidoreductase enzymes like mitochondrial NAD(P)H reduce a yellow tetrazolium 
dye MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide to its 
insoluble form of formazan, which has a purple colour. Reduction of MTT depends on 
the neuronal activity due to level of NAD(P)H. Neurons with low activity reduce MTT 




Fig. 12: Formation of formazan thanks to the activity of vital cells. 
 
Measurement 
A cellular suspension of SH-SY5Y was prepared with a density 2 x 105 cell/mL in 
10% FBS medium. Consequently, 100 μL of suspension were spread into a 96-well 
plate and it was inserted into incubator for 24 hours in a condition of 37°C and 5% of 
CO2 to allow a formation of monolayer. 
To assess the neurotoxicity of coumarin compounds, the cells were treated by adding 
100 μL of DMEM with ESC, SCOP, FRAX and DAPH (2.5-80 µM); while in the 
negative controls, it was added 100 μL of DMEM. Further, cells were incubated for 4 
hours in the same conditions. At least three repetitions of the experiment were made 
for higher accuracy. 
To perform the test, the content of the plate was removed and 100 μL of MTT 
experimental solution were added into each well. After 24 hours of incubation, the 
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solution of tetrazolium salts was eliminated. After removal of MTT, the formazan 
crystals were washed with 150 μL of HBSS and further they were dissolved in 150 μL 
of isopropanol to extract and solubilize the precipitates of formazan. To facilitate the 
solubilisation process the plates were subjected to agitation to obtain a homogeneous 
solution. The amount of formazan was measured at λ = 570 nm (ref. λ = 690 nm) with 
a spectrophotometer (VICTORTM X3, PerkinElmer, Massachusetts, USA). 
 
Expression of results 
Relative cell viability was expressed as percentage compared to control cells and 
calculated using this formula: 
 





ODt = Absorbance of the solution with treated neurons 
ODtn = Absorbance of the solution with untreated neurons 
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7.2.5 Determination of neuroprotective effects 
Principle of the assay 
The amyloid beta peptide (1-42) induced cytotoxicity, in terms of exocytosis and 
intracellular reduction of formazan was determined with the use of tetrazolium salts. 
 
Measurement 
A cellular suspension of SH-SY5Y was prepared with a density 3 x 105 cell/mL in 
10% FBS medium. Consequently, 100 μL of suspension were spread into a 96-well 
plate and it was inserted into incubator for 24 hours in a condition of 37°C and 5% of 
CO2 to allow a formation of monolayer. 
To assess the neuroprotective effects of coumarins, the cells were treated by adding 50 
μL of DMEM 2% FBS with ESC (20 µM) and 50 µL of DMEM 2% FBS with OAβ1-
42 (10µM); in the positive control, it was added 50 μL of DMEM 2% FBS with ESC 
(20 µM) or 50 µL of DMEM 2% FBS with OAβ1-42 (10µM) and 50 µL of DMEM 2% 
FBS; while in the negative controls, it was added 100 μL of DMEM 2% FBS. Further, 
cells were incubated for 4 hours in the same conditions. At least three repetitions of 
the experiment were made for higher accuracy. 
To perform the test, the content of the plate was removed and 100 μL of MTT 
experimental solution were added into each well. After 1 hour of incubation, 10 µL of 
10% v/v tween-20 were added for allow the solubilisation of intracellular granules of 
formazan (TS-MTT). To facilitate the solubilisation process of intracellular granules 
of formazan the 96-well plate was subjected to agitation at 300 rpm for 10 minutes at 
37°C. Then the entire volume of every well was transferred to a new 96-well plate and 
the amount of intracellular formazan was measured at λ = 570 nm (ref. λ = 690 nm) 
with a spectrophotometer (VICTORTM X3, PerkinElmer, Massachusetts, USA).  
Subsequently solutions were carefully aspirated from all the wells using a 
multichannel pipette and further exocytosed crystals of formazan (TI-MTT) were 
dissolved in 100 μL of isopropanol. To facilitate the solubilisation process the 96-well 
plate were subjected to agitation to obtain a homogeneous solution. The amount of 
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exocitosed crystals of formazan was measured at λ = 570 nm (ref. λ = 690 nm) with a 
spectrophotometer (VICTORTM X3, PerkinElmer, Massachusetts, USA). 
 
Expression of results 
Relative amyloid beta peptide (1-42) induced formazan exocytosis was expressed as 
percentage compared to control cells and calculated using this formula: 





ODt = Absorbance of the solution with treated neurons 
ODtn = Absorbance of the solution with untreated neurons 
 
Statistical analysis 
The obtained experimental data were analysed using t-test and GraphPad Prism 
software, version 3.03. Values of P ≤ 0.05 were considered statistically significant.   
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8 Results  
Neurotoxicity 
Initially, we determined the neurotoxicity of ESC, SCOP, FRAX and DAPH. SH-
SY5Y cells were incubated for 24 hours with various concentrations of the studied 
compounds (2.5-80µM). At the end of incubation, the neuronal viability was measured 
using MTT assay as previously described. The results are expressed as percentage 
compared to control cells. 
 
 
Fig.13: Neuronal viability in SHSY5Y cells after 24 hours of treatment with different 
concentration of ESC, SCOP, FRAX and DAPH. The results refer to at least three independent 
experiments. 
 
The treatment of SH-SY5Y cells with ESC, SCOP, FRAX and DAPH concentrations 
up to 40 μM did not affect neuronal viability. Therefore, we selected the range of 






































Intrinsic antioxidant activity 
To evaluate the intrinsic antioxidant activity of ESC, SCOP, FRAX and DAPH we 
used the DPPH assay. The discoloration was quantified through the measurement of 
decrease in absorbance at 492 nm and it was directly proportional to the antioxidant 
activity. 
We recorded that ESC, FRAX and DAPH possess significant scavenging properties 
against DPPH. ESC shows the strongest quenching capacity against DPPH, followed 
by DAPH. While FRAX is less active than ESC and DAPH in DPPH scavenging. 





Fig. 14: Antioxidant direct activity of ESC, SCOP, FRAX and DAPH. The results are 
expressed as mean ± SD of at least three independent experiments (*** p < 0.001 vs control; 
t-test). 
  




















































































































ROS formation inhibition 
Subsequently, we evaluated the antioxidant activity of ESC, SCOP, FRAX and DAPH 
in SHSY5Y cells against the intracellular t-BuOOH-induced ROS formation. SH-
SY5Y cells were incubated 2 hours with various concentrations of the studied 
coumarins and then treated with t-BuOOH (200 µM) for 30 minutes, in order to allow 
the entrance of the coumarins in SHSY5Y cells before the oxidative treatment.  
We recorded that ESC, FRAX and DAPH (2.5-40 µM) counteract t-BuOOH-induced 




Fig. 15: ROS formation in SHSY5Y cells after 2 hours of treatment with different 
concentrations of ESC, SCOP, FRAX and DAPH and 30 minutes of treatment with t-BuOOH 
(200 µM). The results are expressed as mean ± SD of at least three independent experiments 
(*p<0.05 vs treated with t-BuOOH; **p<0.01 vs treated with t-BuOOH; ***p<0.001 vs treated 
with t-BuOOH; t-test). 
  






















































































































SH-SY5Y cells were therefore incubated for 24 hours with various concentrations of 
the studied coumarins (2.5-40µM) and then treated with t-BuOOH (200 µM) for 30 
minutes. At the end of incubation, the ROS formation was determined using a 
fluorescent probe, H2DCF-DA, as previously described. 





Fig. 16: ROS formation in SHSY5Y cells after 24 hours of treatment with different 
concentrations of ESC, SCOP, FRAX and DAPH and 30 minutes of treatment with t-BuOOH 
(200 µM). The results are expressed as mean ± SD of at least three independent experiments 
(*p<0.05 vs treated with t-BuOOH; **p<0.01 vs treated with t-BuOOH; ***p<0.001 vs treated 
with t-BuOOH; t-test). 
 
  




















































































































Intracellular GSH levels increase 
Then we evaluated the ability of ESC to increase the intracellular GSH levels. SH-
SY5Y cells were incubated for 24 hours with various concentrations of ESC (10-40 
µM). At the end of incubation, GSH levels were measured using a fluorescent probe, 
monochlorobimane, as previously described. We recorded that ESC enhances the total 
GSH levels of SH-SY5Y cells. 
 
 
Fig. 17: Intracellular GSH levels in SHSY5Y cells after 24 hours of treatment with various 
concentration of ESC (10-40 µM). The results are expressed as mean ± SD of at least three 




































Finally, to evaluate the neuroprotective effects of ESC, SH-SY5Y cells were incubated 
for 4 hours with ESC (20µM) and OAβ1-42 (10µM). We observed that ESC is able to 
reduce the Aβ induced toxicity, in terms of exocytosis of formazan. At the end of 
incubation, the ability of ESC to counteract early phase of OAβ1-42-induced 
neurotoxicity was measured by MTT formazan exocytosis. 
 
Fig. 18: Exocytosed formazan levels in SHSY-5Y after 4 hours of treatment with OAβ1-42 
(10µM) and ESC (20 µM). The results are expressed as mean ± SD of at least three 
independent experiments (**p<0.01 vs treated with OAβ; t-test). 




Although the etiology of AD remains unknown, the neuropathological profile is 
associated with memory loss and the presence of numerous plaques and cholinergic 
deficiency because of the degeneration or atrophy of cholinergic neurons in the basal 
forebrain.29 Patients affected by AD exhibit abnormal deposits of Aβ, formation of 
neurofibrillary tangles, increased oxidative stress, and low levels of Ach.30  
Unfortunately, there is no cure for AD, and treatment strategies are especially 
symptomatic. 
To evaluate the potential of coumarins as anti-AD agents, we investigated their 
antioxidant and neuroprotective effects. Using MTT cytotoxicity assay, we could 
select four coumarine compounds in a range of certain concentrations (2.5 and 40 µM) 
that is not associated with neurotoxicity and could be applied in the subsequent studies. 
We observed that OAβ1-42 dramatically enhanced MTT formazan exocytosis, 
resulting in the inhibition of cellular MTT reduction. Basal MTT formazan exocytosis 
and amyloid peptide-enhanced MTT formazan exocytosis were blocked by ESC at 
the concentration of 20 µM. According to the obtained results, we could say that 
among the tested coumarins ESC possess a direct neuroprotective effect against both 
t-BOOH-induced oxidative stress and OAβ1-42 induced neurotoxicity. 
The observed direct cytoprotective action could be ascribed to numerous complex 
mechanisms such as the ability of ESC to prevent the bond between Aβ oligomers and 
membrane. Probably, ESC interacts directly with specific amino acids of amyloid 
peptide through the hydrogen bonds. These amino acids are important for the β 
amyloid aggregation, its bond with the membrane and the subsequent cytotoxicity.31 
The antioxidant activity of the tested coumarins observed in this study correlate with 
the data reported in the scientific literature.32  
Kim et al. 33also tested the protective effect of ESC via scavenging reactive oxygen 
species. The radical scavenging activity was determined by DPPH radical, hydroxyl 
radical, and ROS. In addition, lipid peroxidation, ELISA test, Western blotting and 
immunofluorescence images were utilized for the measurement. In this study, ESC 
exhibited DPPH radical scavenging, hydroxyl radical scavenging, and intracellular 
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ROS scavenging activities. The scavenging activity of ESC resulted in the protection 
of cells from lipid peroxidation, protein carbonyl, and DNA damage induced by H2O2. 
Further, ESC recovered cell viability exposed to H2O2.
33 
Moreover, in another study, Ali et al.32 confirmed the activity of coumarins isolated 
from A. decursiva and A. capillaris against AChE, BChE and BACE1, which further 
favour the use of coumarines like ESC and DAPH as potential treatment approaches 
for AD. They used the colorimetric determination of acetylcholinesterase activity to 
measure inhibitory activities of isolated coumarins towards AChE, BChE and BACE1. 
The inhibitory activity of ESC and DAPH towards AChE with IC50 6.13 abd 11.57 µM 
were good. In addition, BACE1 inhibitory activity was strong having IC50 7.67 and 
11.19 µM. ESC and DAPH showed also a good inhibition activity towards BChE, 
concretely with IC50 9.29 and 8.66 µM. To follow the results of this study, they 
performed molecular docking simulations using Autodock 4.2. They simulated 
interactions between BACE1 and coumarins and they confirmed that ESC and DAPH 
could prevent AD by targeting the formation of β-amyloid. Coumarins interact with 
the BACE1 through hydrogen bonds. This fact showed that hydrogen bonding and 
carboxylic groups might result in more effective enzyme inhibition.32 Coumarins, 
which have a catechol group such as ESC, FRAX and DAPH, possess significant free 
radical scavenging activity and inhibitory effects on lipid peroxidation.34 Substitution 
with a methoxyl or glycosyl group probably reduces the antioxidant activity like in the 
case of scopoletin.32 
The relationship between structure and the activity could explain the results of this 
thesis that confirmed that ESC is a perspective compound for the treatment of AD. It 
has the highest antioxidant and cytoprotective capacity of tested coumarins. The 
structure of esculetin contains hydroxyl groups, which can interact easily with the 
specific part of enzymes like AChE, BChE and BACE1, which are involved in the 
pathogenesis of AD. 
DAPH, which also contains hydroxyl groups showed good scavenging activity against 
DPPH. DAPH also determined its antioxidant capacity towards ROS formation. 
Although, DAPH had good antioxidant and scavenging profile, ESC showed the best 
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properties and thus we focused on the tests performed with ESC. The lower effect of 
FRAX and SCOP could be explained by their chemical structures.  
In addition, 20µg of ESC were administered intracerebroventricularly into mice.35 In 
this in vivo study, they investigated the neuroprotective effect of ESC on cerebral 
ischemia. ESC significantly reduced neurological deficit after 75 minutes of ischemia 
and 24 hours of reperfusion. ESC also demonstrated its post neuroprotective effect 
when administered after 4 hours of reperfusion. In this study, ESC also determined the 
properties mentioned in 5.2.3,35 
Our results coincide with the results of studied mentioned before. ESC is the most 
tested compound of coumarins, because of its great results and promising utilization. 
Results acquired in this research could contribute to a new possible treatment of AD 




This experimental thesis was focused on neuroprotective and antioxidant properties of 
natural coumarins - ESC, DAPH, SCOP, and FRAX. 
The results highlight that ESC possess significant neuroprotective effects compared to 
the other coumarins. In particular, our results showed the ability of ESC to prevent and 
counteract t-BOOH- and OAβ-induced neurotoxicity in SH-SY5Y cells.  
Our study promotes further in vivo evaluation of ESC effect in the treatment of 
Alzheimer using relevant animal models and evaluate the potential therapeutic profile 
of ESC as a novel neuroprotective agent. Moreover, ESC could represent a privileged 
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